1. In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.
- Author
-
Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, Van Overmeir C, Rosanas-Urgell A, Van Geertruyden JP, D'Alessandro U, and Erhart A
- Subjects
- Antimanic Agents administration & dosage, Artemether, Lumefantrine Drug Combination, Artemisinins administration & dosage, Burkina Faso epidemiology, Drug Combinations, Drug Resistance genetics, Genetic Variation drug effects, Genetic Variation genetics, Humans, Malaria, Falciparum epidemiology, Malaria, Falciparum genetics, Plasmodium falciparum drug effects, Quinolines administration & dosage, Antimanic Agents therapeutic use, Artemisinins therapeutic use, Ethanolamines therapeutic use, Fluorenes therapeutic use, Malaria, Falciparum drug therapy, Membrane Transport Proteins genetics, Multidrug Resistance-Associated Proteins genetics, Plasmodium falciparum genetics, Protozoan Proteins genetics, Quinolines therapeutic use
- Abstract
Plasmodium falciparum Pfcrt-76 and Pfmdr1-86 gene polymorphisms were determined during a clinical trial in Burkina Faso comparing the efficacies of dihydroartemisinin-piperaquine (DHA-PPQ) and artemether-lumefantrine (AL). Significant selection of Pfcrt-K76 was observed after exposure to AL and DHA-PPQ, as well as selection of Pfmdr1-N86 after AL but not DHA-PPQ treatment, suggesting reverse selection on the Pfcrt gene by PPQ. These results support the rational use of DHA-PPQ in settings where chloroquine (CQ) resistance is high., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF